HanchorBio to Hold May 11 Investor Presentation Ahead of Planned Taiwan Innovation Board Listing
Clinical-stage biotech to outline platform, lead pipeline assets, and partnering progress ahead of planned market debut
[Taipei, Shanghai, San Francisco | May 8, 2026] – HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that it will hold an investor presentation on May 11 ahead of its planned listing on the Taiwan Innovation Board later this month.
The presentation is expected to highlight HanchorBio’s proprietary FBDB™ platform, progress across its lead clinical programs, business development activity, and broader growth strategy as the company prepares for its next phase as a publicly listed biotech.
Founded in 2020 by Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer, HanchorBio is focused on developing multifunctional biologics designed to address complex disease biology across innate and adaptive immune pathways. The company currently has eight drug candidates across research, development, and process development, with HCB101 and HCB301 as its two most advanced clinical-stage programs.
HCB101, an AI-guided, structurally engineered SIRPα-IgG4 Fc fusion protein targeting the CD47-SIRPα axis, is being evaluated in an ongoing Phase 1b/2a study and has demonstrated antitumor activity across multiple solid tumor settings, including head and neck, gastric, triple-negative breast, and colorectal cancers. The program has received the U.S. Food and Drug Administration Orphan Drug Designation for gastric cancer.
HCB301 is a tri-functional fusion protein designed to address three key immune escape pathways in tumors. Phase 1 clinical trials have been initiated in the United States, mainland China, and Taiwan.
“Our strategy is centered on building differentiated best-in-class and first-in-class drug programs with global development and partnering potential,” said Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio. “We believe HCB101 and HCB301 represent two distinct examples of how our platform can generate novel biologics designed to address important limitations in current immuno-oncology approaches.”
HanchorBio has also established an early business development track record. In 2024, the company entered into a licensing agreement for HCB101 with a total potential value of up to US$202 million, granting Henlius exclusive development and commercialization rights in mainland China and certain other territories. The company is also engaged in global partnering discussions with multiple international pharmaceutical companies, including certain partners conducting due diligence.
Beyond oncology, HanchorBio is advancing additional biologic candidates based on the FBDB™ platform, including HCB206 for autoimmune diseases, which is expected to progress toward clinical development. In April 2026, the company also announced a collaboration with National Yang Ming Chiao Tung University to expand its capabilities in AI-enabled drug discovery.
HanchorBio has attracted backing from institutional investors, including Anfu Healthcare and Panacea Venture. Dr. Liu currently holds approximately 40% of the company’s shares, reflecting significant founder ownership and long-term alignment with shareholders.
The planned Taiwan Innovation Board listing would mark an important milestone in HanchorBio’s transition from a privately funded R&D-stage biotech to a broader capital-markets-facing clinical-stage company. The company intends to continue advancing HCB101 and HCB301, pursue additional strategic collaborations, and prepare future IND submissions in autoimmune disease as it expands its pipeline and global development footprint.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics intended to modulate innate and adaptive immune pathways with structural control over safety, exposure, and manufacturability. HanchorBio is advancing a portfolio of differentiated biologics designed to address significant unmet medical needs through innovative molecular engineering and scalable CMC strategies.
漢康-KY上市前業績發表會 5/11登場
FBDB核心平台構築抗癌護城河 瞄準千億美元商機
專注創新藥物開發的漢康-KY（股票代碼：7827）將於5月11日舉辦上市前業績發表會，預計5月底前掛牌創新板上市。
【創新板上市前業績發表會資訊】
- 日 期：115年5月11日（星期一）
- 入場時間：14:00入場
- 開始時間：14:30準時開始
- 地 點：台北遠東香格里拉 3樓宴會廳（台北市大安區敦化南路二段201號）
請點擊以下報名網址參加活動：https://2vx.io/tdbkL35
漢康-KY是全球少數擁有三功能融合蛋白生物藥技術的次世代免疫療法公司，創辦人兼董事長劉世高，曾任職於BMS（必治妥施貴寶）、Amgen（安進）等跨國藥廠，累積豐富技術與經驗，更參與創辦復宏漢霖，帶領團隊首開中國大陸新藥領域的多項記錄。2020年回台灣創辦漢康-KY，聚焦癌症與自體免疫疾病二大領域投入研發，並吸引安富大健康有限合夥、潘納西亞創投（Panacea Venture）等指標性機構投資人注資，為公司提供穩健的財務與戰略資源。其中，劉世高個人持股達四成，展現經營權穩定且看好公司長期發展的價值。
漢康-KY的核心技術FBDB™平台採模組化設計，可突破傳統生物藥在結構與功能上的限制，支援多靶點與多功能生物藥開發。該平台不僅支持單一產品研發，更具備持續產生多項研發資產的能力，目前已有8種藥物進行研發及製程開發，其中HCB101及HCB301二大候選新藥率先進入臨床試驗階段。
HCB101正執行1b/2a期臨床試驗，在多種癌症中觀察到抗腫瘤活性，其中以頭頸癌、胃癌、三陰性乳癌及結直腸癌等適應症表現尤為突出，展現具潛力的廣譜抗腫瘤特性，並獲美國FDA授予治療胃癌的孤兒藥資格認定。
HCB301則是針對腫瘤的三條主要免疫逃脫路徑同時克服的新型三功能融合蛋白藥物，在全球範圍內屬於稀缺產品，目前分別在美國、中國大陸、台灣啟動一期臨床試驗。
劉世高表示，漢康-KY的研發策略只做「同類最優」（Best-in-class）及「首創新藥」（First-in-class）。HCB101透過獨特的差異化分子設計，克服傳統CD47藥物在療效與副作用（血液毒性）無法兼顧的痛點，展現高安全性與抗腫瘤活性，是靶向CD47同類最佳藥物（第3.5代）。
至於HCB301，在全球臨床開發中2,800多個抗體或融合蛋白候選項目，三功能生物藥物僅占3.1%，依然稀少且珍貴。此外，無論是HCB101或HCB301，從藥物分子發現到正式遞交臨床試驗申請（IND），開發週期分別僅2.3年、3.5年，甚至最新一項開發中新藥，開發時程少於兩年，遠低於歐美大廠平均的5.5年，展現極高的研發轉化效率。
漢康-KY在商務拓展與產品線開發方面，同樣展現高效的執行能力。HCB101在去年以2.02億美元完成早期授權，將中國大陸與其他特定國家等地區的市場開發與銷售權利獨家授予復宏漢霖，目前持續與超過10家世界排名國際藥廠洽談全球授權，其中已有潛在合作對象進入盡職調查階段。
此外，隨著HCB301的一期臨床數據逐步釋出，也規劃展開探索性合作洽談。公司透過授權、共同開發或併購等多種獲利模式，瞄準全球逾千億美元的免疫腫瘤市場商機，加速新藥的商化腳步，以期創造營收挹注的機會。
在產品線開發方面，除了基於FBDB™平台為基礎的多款生物藥，如自體免疫疾病新藥HCB206等將陸續進入臨床外，也持續在國內外尋找新的合作機會。今年4月間，漢康-KY即攜手國立陽明交大共同進軍AI藥物開發領域，進一步豐富產品線組合。
劉世高指出，公司成立至今雖未滿六年，已逐步累積多項新藥產品線，並且繳出亮眼的授權成績單，代表產品與技術平台獲得國際藥廠認可。漢康-KY於去年6月登錄興櫃，未滿1年即申請創新板上市，更標誌公司正從研發型積極轉向商業化成長階段的關鍵里程碑。
展望未來，漢康-KY將持續深耕免疫腫瘤療法，整合美、中、台三地的臨床資源與研發實力，加速推動HCB101與HCB301的臨床進度與全球授權，並規畫提交旗下針對自體免疫疾病的創新藥物（如HCB206）的IND申請；此外，透過戰略結盟擴大布局未滿足醫療需求的產品線，力求在全球生醫產業中建立無可取代的市場護城河，蓄積永續成長動能，且為股東創造長期價值。
關於漢康-KY：
英屬開曼群島商漢康生技股份有限公司（以下簡稱“漢康-KY”，股票代碼：7827）成立於2020年，由具豐富國際藥物開發與運營經驗的劉世高博士創辦。公司專注於腫瘤免疫藥物研發，透過自主建立的核心「FBDB多功能融合蛋白技術平台」開發出8+種創新蛋白生物藥，具有廣譜抗癌潛力，可抑制多種實體瘤及血液腫瘤，並持續取得多項專利。其中HCB101與HCB301已進入臨床試驗階段，而HCB101在2025年6月更完成首項國際授權，總授權金達2.02億美元。漢康-KY的策略是以多功能生物藥克服現行採取免疫療法與化療並行的高失敗率，同時藉由啟動先天性免疫和適應性免疫體系以摧毀腫瘤，致力提供高效且可負擔的新一代腫瘤免疫治療方案，解決未滿足的醫療需求。更多的公司資訊請詳見官網https://www.hanchorbio.com/ 。
聲明：
本新聞稿及同時發佈之相關資訊內含有預測性敘述；其內容乃根據既有之風險及可能的不確定性進行判斷及預測，包括：市場因素與其他非漢康-KY（以下簡稱本公司）所能掌控之原因。這些預測性敘述是基於現況的預測和評估，除非基於法律的要求，本公司不負日後更新之責。